{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:21:24Z","timestamp":1793733684933,"version":"4.6.1"},"reference-count":97,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,6,7]]},"DOI":"10.1080\/10428194.2025.2466101","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:53:33Z","timestamp":1740012813000},"page":"1176-1188","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy"],"prefix":"10.1080","volume":"66","author":[{"given":"Christine","family":"Gruessner","sequence":"first","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-4729","authenticated-orcid":false,"given":"Clare","family":"Sun","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18418"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2402472"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_3_3_10_1","unstructured":"US Food and Drug Administration. Project Orbis: FDA approves acalabrutinib for CLL and SLL. [cited 2019 Nov 21]. 2019. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/project-orbis-fda-approves-acalabrutinib-cll-and-sll"},{"key":"e_1_3_3_11_1","unstructured":"US Food and Drug Administration. FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma. [cited 2023 Jan 19]. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma"},{"key":"e_1_3_3_12_1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. [cited 2023 Dec 1]. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003715"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142235"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02329-y"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023659"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014206"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008325"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32502"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000854"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11932"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003632"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173547"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967496.62332.46"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1409362111"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21406"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.153"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.06.006"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020240"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2933"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006783"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01123-6"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008447"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811752"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1435268"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626846"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2013"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3870"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3217"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065x.1997.tb00963.x"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.017905"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003179"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171288"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015014"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007812"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-688796"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018882555"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179198"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019706"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080764"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127566"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1409"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001956"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.03.011"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1105779"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8"},{"key":"e_1_3_3_76_1","unstructured":"US Food and Drug Administration. BREYANZI (lisocabtagene maraleucel). [cited 2024 Mar 14 March]. 2024. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.111"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"e_1_3_3_80_1","unstructured":"US Food and Drug Administration. Duvelisib: US FDA oncologic drugs advisory committee meeting. the Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies. Available from: https:\/\/www.fda.gov\/media\/161693\/download."},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792333"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174750"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3934"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00452-7"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18357"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007708"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.211"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016934"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164772"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180109"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184835"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01293-X"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-830992"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009686"},{"key":"e_1_3_3_96_1","first-page":"1546171","volume-title":"Presented at: 2023 international workshop on CLL; October 6-9","author":"Kater AP.","year":"2023","unstructured":"Kater AP. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b\/2 EPCORE CLL-1 trial expansion cohort. In Presented at: 2023 international workshop on CLL; October 6-9. Boston (MA); 2023. p. 1546171."},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199708"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009517"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2466101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:20:08Z","timestamp":1757924408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2466101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,7]]}},"alternative-id":["10.1080\/10428194.2025.2466101"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2466101","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}